PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
From this randomized controlled study, we aim to:
A.Do do cardiovascular risk stratification of renal transplant recipients who are followed up
in Hamed Al-Essa organ transplant center of Kuwait.
B. To compare the effectiveness of a PCSK9 inhibitor plus maximum tolerated statin therapy
vs. maximum tolerated statin therapy alone in the reduction of major cardiovascular events
among renal transplant recipients with cardiovascular disease.
C. To compare the effectiveness of a PCSK9 inhibitor plus maximum tolerated statin therapy
vs. maximum tolerated statin therapy alone in terms of LDL-C-lowering, muscle symptoms, and
quality of life.
D. To compare patient adherence to the different treatment protocols.